IRIS UniCatt

Ferrandina, Maria Gabriella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.058
AS - Asia 11.043
EU - Europa 10.641
SA - Sud America 2.095
Continente sconosciuto - Info sul continente non disponibili 1.417
AF - Africa 303
OC - Oceania 26
AN - Antartide 1
Totale 40.584
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.655
SG - Singapore 5.154
DE - Germania 2.850
CN - Cina 2.556
SE - Svezia 1.761
BR - Brasile 1.720
IT - Italia 1.476
FR - Francia 1.009
VN - Vietnam 1.005
UA - Ucraina 716
PL - Polonia 681
IN - India 539
IE - Irlanda 513
GB - Regno Unito 497
ID - Indonesia 326
FI - Finlandia 311
RU - Federazione Russa 273
HK - Hong Kong 264
JP - Giappone 241
BD - Bangladesh 212
CA - Canada 195
TR - Turchia 153
AR - Argentina 138
NL - Olanda 105
IQ - Iraq 101
MX - Messico 101
BE - Belgio 75
ZA - Sudafrica 72
ES - Italia 66
PK - Pakistan 63
AT - Austria 62
EC - Ecuador 56
CI - Costa d'Avorio 54
SA - Arabia Saudita 46
IR - Iran 43
LT - Lituania 42
KR - Corea 41
MA - Marocco 40
CL - Cile 37
CO - Colombia 37
VE - Venezuela 37
PY - Paraguay 34
CZ - Repubblica Ceca 33
UZ - Uzbekistan 33
KE - Kenya 32
JO - Giordania 31
EG - Egitto 27
RO - Romania 26
AE - Emirati Arabi Uniti 25
PH - Filippine 24
CH - Svizzera 22
IL - Israele 22
JM - Giamaica 20
AU - Australia 19
TN - Tunisia 19
MY - Malesia 18
EU - Europa 16
BH - Bahrain 15
CR - Costa Rica 14
DZ - Algeria 14
PE - Perù 14
UY - Uruguay 14
AL - Albania 13
AZ - Azerbaigian 13
GR - Grecia 13
NP - Nepal 13
PA - Panama 13
DO - Repubblica Dominicana 12
HU - Ungheria 12
KZ - Kazakistan 12
LB - Libano 12
HR - Croazia 11
OM - Oman 11
SN - Senegal 11
HN - Honduras 10
KG - Kirghizistan 10
MD - Moldavia 10
TT - Trinidad e Tobago 10
ET - Etiopia 9
LV - Lettonia 9
PS - Palestinian Territory 8
PT - Portogallo 8
TW - Taiwan 8
BO - Bolivia 7
RS - Serbia 7
AM - Armenia 6
BG - Bulgaria 6
GE - Georgia 6
MT - Malta 6
NO - Norvegia 6
NZ - Nuova Zelanda 6
AO - Angola 5
NI - Nicaragua 5
XK - ???statistics.table.value.countryCode.XK??? 5
DK - Danimarca 4
GH - Ghana 4
GT - Guatemala 4
MN - Mongolia 4
PR - Porto Rico 4
SK - Slovacchia (Repubblica Slovacca) 4
Totale 39.112
Salva come PNG Salva come JPEG
Città #
Singapore 2.833
Chandler 1.875
San Jose 1.502
Ashburn 1.412
Warsaw 609
Beijing 579
Dublin 498
Jacksonville 444
San Mateo 408
New York 370
Ho Chi Minh City 348
Wilmington 312
Jakarta 301
Rome 276
Lauterbourg 275
Los Angeles 275
Nanjing 268
Hanoi 251
Hangzhou 242
Hong Kong 233
Ann Arbor 223
Houston 211
Tokyo 209
The Dalles 199
Boston 186
Frankfurt am Main 185
Milan 183
Dearborn 178
Hyderabad 176
Hefei 171
Dallas 168
Fairfield 156
São Paulo 150
Nürnberg 149
Moscow 148
Woodbridge 143
Princeton 138
Cattolica 137
Munich 134
Seattle 131
Marseille 126
Lawrence 122
Santa Clara 116
Helsinki 107
Redwood City 105
Chicago 98
Buffalo 93
Bremen 84
Nanchang 83
Atlanta 82
Council Bluffs 80
Boardman 77
Izmir 74
Brussels 69
Da Nang 66
Orem 66
Brooklyn 65
Cambridge 62
London 62
Leawood 60
St Louis 59
Zhengzhou 59
Lancaster 58
Abidjan 54
Strasbourg 54
University Park 54
Shanghai 53
Mountain View 52
Toronto 52
Detroit 48
Norwalk 48
Phoenix 48
Kraków 47
Kunming 46
Belo Horizonte 45
Denver 44
Changsha 43
Düsseldorf 43
Haiphong 43
Paris 43
Turku 43
Hebei 42
Johannesburg 42
Rio de Janeiro 42
Chennai 41
Kent 41
Nuremberg 41
Redmond 41
Shenyang 41
Guangzhou 40
Jiaxing 39
Montreal 39
Amsterdam 38
San Francisco 38
Augusta 37
Seoul 35
Vienna 34
Baghdad 33
Dhaka 33
Tianjin 33
Totale 20.149
Salva come PNG Salva come JPEG
Nome #
Clinical outcome of recurrent locally advanced cervical cancer (lacc) submitted to primary multimodality therapies 866
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 525
Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study 402
Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study 382
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 367
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence 318
Prognostic role of topoisomerase-IIalpha in advanced ovarian cancer patients 311
Multidisciplinary Tumor Board Smart Virtual Assistant in Locally Advanced Cervical Cancer: A Proof of Concept 306
An exploratory assessment of early and delta PET radiomic features for outcome prediction in locally advanced cervical cancer 294
Machine-learning prediction of treatment response to stereotactic body radiation therapy in oligometastatic gynecological cancer: A multi-institutional study 287
Evaluation of quality of life and emotional distress in endometrial cancer patients: A 2-year prospective, longitudinal study 240
Paclitaxel, epirubicin, and cisplatin (TEP) regimen as neoadjuvant treatment in locally advanced cervical cancer: long-term results 236
Long-term analysis of clinical outcome and complications in locally advanced cervical cancer patients administered concomitant chemoradiation followed by radical surgery 233
Short-Course Accelerated Radiotherapy in Palliative Treatment of Advanced Pelvic Malignancies: A Phase I Study 233
Laparoscopic staging of apparent early stage ovarian cancer: results of a large, retrospective, multi-institutional series 232
I nuovi mezzi di contrasto nello studio delle patologie ginecologiche. Applicazioni diagnostiche e prospettive terapeutiche. 230
Mammography before post-operative radiotherapy in conservatively managed breast cancer patients: is it useful? 230
Transvaginal ultrasonography and magnetic resonance imaging for assessment of presence, size and extent of invasive cervical cancer. 226
Neoadjuvant chemotherapy followed by conization in stage IB2–IIA1 cervical cancer larger than 2 cm: a pilot study 202
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 201
Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study 200
Adrenomedullin in Ovarian Cancer: Foe In Vitro and Friend In Vivo? 198
Stereotactic body radiotherapy and poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a knowledge and attitudes survey in collaboration with the Italian Association of Radiation Oncology (AIRO) and Multicenter Italian Trials in Ovarian Cancer (MITO) groups 196
Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study 196
Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial 196
Evaluation of early regression index as response predictor in cervical cancer: A retrospective study on T2 and DWI MR images 195
Should laparoscopy be included in the work-up of advanced ovarian cancer patients attempting interval debulking surgery? 195
Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment? 194
Preoperative local staging of endometrial cancer: transvaginal sonography vs. magnetic resonance imaging. 187
Quality of life and psychological distress in locally advanced cervical cancer patients administered pre-operative chemoradiotherapy 186
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience. 186
A complete pathological response to treatment in a young patient with locally advanced minimal deviation adenocarcinoma of the uterine cervix undergoing chemoradiation followed by radical surgery 185
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. 184
Neuroendocrine stress response in patients undergoing benign ovarian cyst surgery by laparoscopy, minilaparotomy, and laparotomy 180
Is frozen section analysis of pelvic lymph nodes accurate in locally advanced cervical cancer patients administered preoperative chemoradiation? 180
Ultrasound contrast examination to discriminate benign and malignant adnexal masses 179
Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. 179
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 179
Volumetric intensity modulated arc therapy for stereotactic body radiosurgery in oligometastatic breast and gynecological cancers: feasibility and clinical results 178
Sonographic imaging of urinoma 176
3D conformal postoperative radiotherapy with concomitant boost in uterine cancer: results of a phase I-II study (ADA-RT-1) 176
Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups 176
Extracranial radiosurgery with volumetric modulated arc therapy: Feasibility evaluation of a phase I trial 173
Ultrasound evaluation of intra-abdominal sites of disease to predict the likelihood of suboptimal cytoreduction in advanced ovarian cancer: a propective study 172
Stereotactic radiosurgery (SRS) with volumetric modulated arc therapy (VMAT): interim results of a multi-arm phase I trial (DESTROY-2) 172
Imaging in gynecological disease (1): ultrasound features of metastases in the ovaries differ depending on the origin of the primary tumor 171
PRospective Imaging of CErvical cancer and neoadjuvant treatment (PRICE) study: role of ultrasound to predict partial response in locally advanced cervical cancer patients undergoing chemoradiation and radical surgery 171
A case of isolated ovarian recurrence from vulvar carcinoma. 170
The role of 18F-FDG-PET/CT in predicting the histopathological response in locally advanced cervical carcinoma treated by chemo-radiotherapy followed by radical surgery: a prospective study 170
Malignant transformation of Madelung's disease in a patient with a coincidental diagnosis of breast cancer: a case report. 168
Can radicality of surgery be safely modulated on the basis of MRI and PET/CT imaging in locally advanced cervical cancer patients administered preoperative treatment? 168
Preoperative local-regional staging of endometrial cancer: transvaginal sonography versus magnetic resonance imaging 166
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase ii study (ester-1). 165
Forward planned intensity modulated radiotherapy (IMRT) for whole breast postoperative radiotherapy. Is it useful? When? 165
Color Doppler sonographic features of a Krukenberg tumor in pregnancy 164
Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison 164
Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study 162
High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes 162
Chemoradiation with concomitant boost followed by radical surgery in locally advanced cervical cancer: a dose-escalation study. 161
Uterine inversion in association with uterine sarcoma: a case report with MRI findings and review of the literature 160
Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review 160
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients 159
Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial 158
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial 157
A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups 156
Laparoscopic surgical management of localized recurrent ovarian cancer: a single-institution experience 155
Female pelvis 154
Prognostic role of the recepteur d'origine nantais (RON) expression in ovarian cancer patients 154
Minimally invasive salvage lymphadenectomy in gynecological cancer patients: A single institution series 154
Epidermal growth factor levels in human breast cyst fluid 153
Characteristics and patterns of care of endometrial cancer before and during COVID-19 pandemic 153
3D conformal postoperative radiotherapy with concomitant boost in uterine cancer: results of a phase I-II study (ADA-RT-1) 152
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 151
Robotic Surgery in Elderly and Very Elderly Gynecologic Cancer Patients 149
MRI in uterine cancers with uncertain origin: Endometrial or cervical? Radiological point of view with review of the literature 148
The 'lead vessel': a vascular ultrasound feature of metastasis in the ovaries. 148
The interaction of β-arrestin1 with talin1 driven by endothelin A receptor as a feature of α5β1 integrin activation in high-grade serous ovarian cancer 147
Epithelial ovarian cancer and brain metastases: might the BRCA status, PARP inhibitor administration, and surgical treatment impact the survival? 146
Outcomes of High-Grade Cervical Dysplasia with Positive Margins and HPV Persistence after Cervical Conization 146
Prognostic Significance of Ultrasound Characteristics and Body Mass Index in Patients with Apparent Early-Stage Cervical Cancer: A Single-Center, Retrospective, Cohort Study 145
Concomitant boost plus large-field preoperative chemoradiation in locally advanced uterine cervix carcinoma: Phase II clinical trial final results (LARA-CC-1) 145
Long-term prospective longitudinal evaluation of emotional distress and quality of life in cervical cancer patients who remained disease-free 2-years from diagnosis 145
EROS study: Evaluation between high-dose-rate and low-dose-rate vaginal interventional radiotherapy (brachytherapy) in terms of overall survival and rate of stenosis 143
Human papillomavirus independent status on pathologic response and outcomes in locally advanced cervical cancer managed with chemoradiotherapy followed by surgery 142
Concomitant boost dose escalation plus large-field preoperative chemoradiation in locally advanced carcinoma of the uterine cervix: results of a phase I study (LARA-CC-1). 142
Role of comorbidities in locally advanced cervical cancer patients administered preoperative chemoradiation: Impact on outcome and treatment-related complications. 142
Successful Treatment of a Young Patient with Locally Advanced Clear Cell Adenocarcinoma of the Uterine Cervix Undergoing Chemoradiation Followed by Radical Surgery 142
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 141
Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey 141
The relevance of prelamin A and RAD51 as molecular biomarkers in cervical cancer 141
Receptors for epidermal growth factor and steroid hormones in primary colorectal tumors 140
Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases 140
How to Select Early-Stage Cervical Cancer Patients Still Suitable for Laparoscopic Radical Hysterectomy: a Propensity-Matched Study 140
Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients. 139
Simultaneous Integrated Boost Volumetric Modulated Arc Therapy in the Postoperative Treatment of High-Risk to Intermediate-Risk Endometrial Cancer: Results of ADA II Phase 1-2 Trial 139
Cervical cancer patterns of care in Italy: A radiation oncology survey of MITO and AIRO GYN groups 139
Radiomics-based prediction of two-year clinical outcome in locally advanced cervical cancer patients undergoing neoadjuvant chemoradiotherapy 139
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study 138
Successful multimodal treatment of a breast cancer patient with a recurrence invading the chest wall 138
Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850) 138
Totale 19.285
Salva come PNG Salva come JPEG
Categoria #
all - tutte 165.699
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 165.699
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.293 0 157 47 255 121 64 46 407 108 192 387 509
2022/20235.153 689 708 409 780 339 628 223 384 624 138 153 78
2023/20242.461 100 725 67 157 73 319 178 87 47 96 313 299
2024/20255.404 134 135 387 186 481 177 226 244 827 661 1.037 909
2025/202613.925 2.081 393 822 1.517 2.316 819 2.438 765 955 1.003 474 342
2026/20271.828 573 1.255 0 0 0 0 0 0 0 0 0 0
Totale 40.584